Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 71

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 71
---
 the Sponsor, $204,000 in deferred offering costs were paid by the Sponsor and $94,574 in expenses
were paid by the Sponsor. As of June 30, 2025 and December 31, 2024, there was $0 and $662,324, respectively, outstanding under the Promissory
Note.

Advisory Services

The Company received advisory services from an
uncompensated related party advisor, husband to the CEO of the Company (the “Advisor”). The role of such advisor is to assist
in the day-to-day transactions of the Company.

CFO Agreement

Effective July 1, 2024, the Company’s CFO
has a consulting agreement with the Company. For the three and six months ended June 30, 2025, the Company has incurred $8,825 and $22,764
of expense reported in general and administrative costs on the unaudited statement of operations, respectively. As of June 30, 2025 and
December 30, 2024, $20,000 and $0, respectively, was paid by the Advisor. As of June 30, 2025 and December 31, 2024, $0 and $1,300 is
included in accounts payable and accrued expenses on the balance sheets.

Related Party Loans

In order to finance transaction costs in connection
with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may,
but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a
Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company.
Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination
does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds
held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital
Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either
be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such
Working Capital Loans may be convertible into units of the post